Skip to main content
SpringerLink
Log in

Treatment of pancreatic insufficiency in CF requires a cautious approach

  • Drug Reactions and Interactions
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sanchez I, Guiraldes E. Drug management of noninfective complications of cystic fibrosis. Drugs 1995; 50(4): 626–35

    Article  PubMed  CAS  Google Scholar 

  2. Taylor CJ. The problem with high-dose pancreatic enzyme preparations. Drug Saf 1994; 11(2): 75–9

    Article  PubMed  CAS  Google Scholar 

  3. Heijerman HG, Lamers CB, Bakker W. Omeprazole enhances the efficacy of pancreatin (Pancrease) in cystic fibrosis. Ann Intern Med 1991; 114: 200–1

    PubMed  CAS  Google Scholar 

  4. Darling PB, LePage G, LeRoy C, et al. Effect of taurine supplements on fat absorption in cystic fibrosis. Pediatr Res 1985; 19: 578–82

    Article  PubMed  CAS  Google Scholar 

  5. Smyth RL, van Velzen D, Smyth AR, et al. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet 1994; 343: 85–6

    Article  PubMed  CAS  Google Scholar 

  6. Smyth RL, Ashby D, O’Hea U, et al. Fibrosing colonopathy in cystic fibrosis: results of a case-control study. Lancet 1995; 346: 1247–51

    Article  PubMed  CAS  Google Scholar 

  7. Croft NM, Marshall TG, Ferguson A. Gut inflammation in children with cystic fibrosis on high-dose enzyme supplements. Lancet 1995; 346: 1265–7

    Article  PubMed  CAS  Google Scholar 

  8. Uchegbu IF, Florence AT. Adverse drug events related to dosage forms and delivery systems. Drug Saf 1996; 14(1): 39–67

    Article  PubMed  CAS  Google Scholar 

  9. Fibrosing colonopathy associated with pancreatic enzymes. Curr Prob Pharmacovigil 1995 Nov; 21: 11

  10. British National Formulary No. 31. London: The Pharmaceutical Press, 1996 Mar: 55–6

  11. Martindale. The Extra Pharmacopoeia, 30th ed. London: Pharmaceutical Press, 1993: 1397–8

    Google Scholar 

  12. 1995 Physicians GenRx. St Louis, Missouri: Mosby-Year Book, Inc., 1995: 1494

  13. Briars GL, Griffiths DM, Moore IE, et al. High strength pancreatic enzymes [letter]. Lancet 1994; 343: 600

    Article  PubMed  CAS  Google Scholar 

  14. MacSweeney EJ, Oades PJ, Buchdahl R, et al. Relation of thickening of the colon wall to pancreatic-enzyme treatment of cystic fibrosis. Lancet 1995; 345: 752–5

    Article  CAS  Google Scholar 

  15. Jones R, Franklin K, Spicer R, et al. Colonic strictures in children with cystic fibrosis on low-strength pancreatic enzymes [letter]. Lancet 1995; 346: 499

    Article  PubMed  CAS  Google Scholar 

  16. van Velzen D. Colonic strictures in children with cystic fibrosis on low-strength pancreatic enzymes [letter]. Lancet 1995; 346: 499–500

    Article  PubMed  Google Scholar 

  17. Goldberg DM, Durie PR. Biochemical tests in the diagnosis of chronic pancreatitis and in the evaluation of pancreatic insufficiency. Clin Biochem 1993; 26: 253–75

    Article  PubMed  CAS  Google Scholar 

  18. Schwarzenberg SJ, Wielinski CL, Shamieh I, et al. Cystic fibrosis-associated colitis and fibrosing colonopathy. J Pediatr 1995;127: 565–70

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Treatment of pancreatic insufficiency in CF requires a cautious approach. Drugs Ther. Perspect 7, 8–10 (1996). https://doi.org/10.2165/00042310-199607100-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199607100-00003

Search

Navigation